Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
-
Patent number: 8962825Abstract: Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: wherein Q, V and W independently represent —N? or —C?; B is a divalent radical selected from (B1), (B2), (B3), (B4), (B5) and (B6). wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker1]- and -[Linker2]- independently represent a bond, or a divalent linker radical; and R is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— or (b) a radical of formula R-L1-Y1—(CH2)z—.Type: GrantFiled: October 30, 2006Date of Patent: February 24, 2015Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: David Charles Festus Moffat, Sanjay Ratilal Patel, Francesca Ann Day, Andrew James Belfield, Alistair David Graham Donald, Alan Hornsby Davidson, Alan Hastings Drummond
-
Patent number: 8937071Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: March 14, 2014Date of Patent: January 20, 2015Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Hilary Schenck Eidam, Kaushik Raha, Zhen Gong, Huiping Amy Guan, Chengde Wu, Haiying Yang, Haiyu Yu, Zhiliu Zhang, Mui Cheung
-
Publication number: 20140286935Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicant: Glaxosmithkline Intellectual Property Development LimitedInventors: Paul HAMBLIN, Alan Lewis, Thomas Matthew Webb
-
Patent number: 8841463Abstract: Disclosed are 4-amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.Type: GrantFiled: February 9, 2012Date of Patent: September 23, 2014Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Christopher E Neipp, Michael R. Palovich
-
Publication number: 20140275111Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Hilary Schenck EIDAM, Kaushik Raha, Zhen Gong, Huiping Guan, Chengde Wu, Haiying Yang, Haiyu Yu, Zhiliu Zhang, Mui CHEUNG
-
Publication number: 20140256949Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, R4 and R5 are as defined herein, and methods of making and using the same.Type: ApplicationFiled: May 21, 2014Publication date: September 11, 2014Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Linda N. CASILLAS, Adam Kenneth Charnley, Pamela A. Haile, Terry Vincent Hughes, Robert W. Marquis, JR., John F. Mehlmann, Michael Reilly, Joseph J. Romano, Robert R. Singhaus, JR.
-
Publication number: 20140256721Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.Type: ApplicationFiled: April 14, 2014Publication date: September 11, 2014Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
-
Publication number: 20140213599Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.Type: ApplicationFiled: January 23, 2014Publication date: July 31, 2014Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Zehong WAN, Yingxia Sang, Qing Zhang
-
Publication number: 20140193517Abstract: Methods are provided for selecting a new therapeutic indication for at least one first pharmaceutical comprising the steps of: generating a drug-side effect (SE) association for said at least one first pharmaceutical; generating a disease-side effect (SE) association for at least one disease or disorder and at least one second pharmaceutical intended for treatment of said at least one disease or disorder; determining an association strength between the drug-side effect (SE) association and the disease-side effect (SE) association; selecting said at least one disease or disorder as a new therapeutic indication for said at least one first pharmaceutical if said at least one first pharmaceutical induces at least one side effect which is the same as at least one side effect induced by at least one second pharmaceutical intended for treatment of said at least one disease or disorder.Type: ApplicationFiled: August 17, 2012Publication date: July 10, 2014Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Pankaj Agarwal, Lun Yang
-
Patent number: 8765743Abstract: The invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.Type: GrantFiled: June 3, 2009Date of Patent: July 1, 2014Assignee: Glaxosmithkline Intellectual Property Development LimitedInventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, Juliet Kay Simpson, Christian Alan Paul Smethurst
-
Patent number: 8735390Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.Type: GrantFiled: September 6, 2011Date of Patent: May 27, 2014Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
-
Publication number: 20140080830Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): And salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: ApplicationFiled: November 25, 2013Publication date: March 20, 2014Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
-
Patent number: 8658635Abstract: The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.Type: GrantFiled: June 3, 2009Date of Patent: February 25, 2014Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, John Edward Robinson, Juliet Kay Simpson, Christian Alan Paul Smethurst
-
Patent number: 8656911Abstract: There is provided an actuation counter comprising a driver feature having one or more driver elements, which driver feature is arranged for drivable movement in response to an actuation; and a count member including one or more drive receipt elements arranged thereon for receipt of drive from said one or more driver elements of the driver feature for drivable movement of the count member. The driver feature includes one or more brake elements arranged to selectively interact with the count member to prevent overrun thereof when registering a count of an actuation. The actuation is suitably arranged for use with a drug dispenser device.Type: GrantFiled: February 17, 2009Date of Patent: February 25, 2014Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventor: David Vincent Elliman
-
Patent number: 8609657Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: October 2, 2012Date of Patent: December 17, 2013Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
-
Publication number: 20130317037Abstract: The present invention provides a method of treating a human with cancer comprising detecting at least one mutation in a PIK3CA gene or at least one mutant protein encoded by said PIK3CA gene from at least one first sample from said human and administering to said human an effective amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide or a pharmaceutically acceptable salt thereof in a pharmaceutical composition if said at least one sample has at least one mutant PI3K protein or a mutation in the PIK3CA gene.Type: ApplicationFiled: November 16, 2011Publication date: November 28, 2013Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Kurtis Earl Bachman, Joel David Greshock
-
Patent number: 8590529Abstract: An actuator for an inhaler for delivering medicament by inhalation, comprising: a housing for receiving a canister which comprises a body which includes a base and a head and defines a chamber containing medicament, and a valve stem which extends from the body and from which medicament is in use delivered on actuation of the canister; an outlet through which a user in use inhales; and a nozzle assembly which provides for delivery of medicament through the outlet, wherein the nozzle assembly comprises a nozzle block which receives the valve stem of the canister and, as a separately-formed component, a nozzle outlet which is fluidly connected to the nozzle block and includes an outlet orifice from which medicament is in use delivered.Type: GrantFiled: August 21, 2007Date of Patent: November 26, 2013Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Gregor John McLennan Anderson, Penelope Ann Burgess, Gary Thomas Crosby, Tristan Fairbrother, Philip William Farr
-
Patent number: 8586583Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): And salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: October 2, 2012Date of Patent: November 19, 2013Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Nigel James Parr
-
Patent number: 8586590Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: October 2, 2012Date of Patent: November 19, 2013Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Nigel James Parr
-
Patent number: 8575162Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: April 28, 2010Date of Patent: November 5, 2013Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr